Tides Express | Novo Nordisk Discloses Amycretin Molecular Structure, Advancing into Phase III Clinical Trials

Jul 16, 2025 09:45 CST Updated 09:45

Novo Nordisk

Insulin Developer and Manufacturer

｜Edited by the Peptide Biotech Content Team

RecentlyDay,Novo NordiskThe molecular structure of Amycretin is officially disclosed.

In June this year, Novo Nordisk announced that based on the current clinical data, it had decided to advance subcutaneous and oral Amycretin into Phase III clinical trials for weight loss after the EOP2 meeting with the FDA. Novo Nordisk plans to initiate the Phase III clinical trial for weight loss with Amycretin in the first quarter of 2026.

In the Phase 1b/2a clinical trial, subcutaneous injection of 1mg, 5mg, and 20mg Amycretin for 36 weeks resulted in weight loss of up to 9.7%, 16.2%, and 22.0%, respectively, with placebo-adjusted weight loss reaching 12%, 18%, and 24%. In terms of safety, the side effects of Amycretin are similar to other incretin-based drugs.

AboutAmycretin

Amycretin is a product developed by Novo Nordisk.Single-molecule long-acting GLP-1 receptor and amylin receptor agonist, aiming to provide efficient and convenient treatment options for overweight or obese adults as well as adult patients with type 2 diabetes.AmylinIt is another hormone related to hunger and satiety, apart from the GLP-1 signaling pathway.Studies show that amylin can reduce energy intake, regulate food choices and preferences, exert glucose regulation through co-secretion with insulin, inhibit postprandial glucagon release, and delay gastric emptying.In addition,Amylin receptors are also expected to synergize with GLP-1 receptor agonists.

AboutNovo Nordisk

Novo Nordisk, founded in 1923, is a global leading biopharmaceutical company headquartered in Copenhagen, the capital of Denmark. Our goal is to drive change to defeat diabetes and other serious chronic diseases such as obesity, rare blood disorders, and endocrine disorders. To achieve this goal, we lead scientific breakthroughs, expand the accessibility of our medicines, and are committed to preventing and ultimately curing these diseases. Novo Nordisk has approximately 47,000 employees across 80 countries and regions worldwide, providing products and services to more than 168 countries and regions globally.

Source:

1. Medical Notes